Who is suitable for a ChondroFiller hip injection

The most practical question at this stage is straightforward: does the pattern of damage in your hip match what ChondroFiller is designed to treat?

The injection is suited to patients with an isolated, focal Grade III or IV chondral defect — meaning a discrete area of cartilage loss rather than damage spread across the whole joint surface. Crucially, the cartilage bordering the defect needs to be healthy and structurally sound; ChondroFiller works by providing a scaffold the surrounding tissue can grow into, so the quality of that border matters. Focal damage linked to femoroacetabular impingement (FAI) is a common presentation within this indication, and published clinical evidence includes patients with FAI-related hip cartilage injury.

Suitability is driven by defect pattern, not age. There is no stated upper age limit for the injection route; a 65-year-old with a focal lesion and intact adjacent cartilage may be as suitable as a 35-year-old with the same picture.

Who is not suitable

Three situations steer patients toward a different pathway rather than the ChondroFiller injection:

• Active joint infection — injection into an infected joint is contraindicated.
• End-stage hip arthritis — where articular cartilage is completely absent, there is no viable scaffold environment for the collagen to integrate.
• Diffuse Kellgren-Lawrence Grade IV osteoarthritis — widespread, joint-wide degeneration is better addressed by other modalities.

Patients seeking a rapid, steroid-type pain response are also unlikely to be appropriate candidates; the repair process develops over months, not days.

Before any treatment decision, an MRI review is mandatory to map the extent of cartilage damage and confirm that the defect pattern fits the indication.

How the collagen scaffold recruits the hip's own repair cells

ChondroFiller Liquid is a purified Type I collagen — the same structural protein that forms the framework of native cartilage — derived from murine tissue using an acid-extraction method that keeps the collagen molecules in their natural, undenatured state. Critically, it contains no donor cells, no synthetic polymer, and no growth factors added from outside: the vial holds only the collagen scaffold itself.

When the solution is placed into the hip joint under ultrasound guidance, it self-polymerises within minutes — the collagen strands cross-link and gel in place even in the fluid-filled joint environment. The result is a stable, three-dimensional matrix that conforms to the defect site.

From that point, the patient's own biology takes over. The gelled scaffold draws mesenchymal stem cells from the surrounding synovium and subchondral bone to the site — it acts, in effect, as a biological homing signal. Those recruited cells migrate into the scaffold, begin to differentiate, and over three to six months progressively deposit fibrocartilage-like repair tissue as the collagen matrix gradually resorbs. The scaffold is replaced by the patient's own material, not a permanent implant.

This process — acellular matrix-induced chondrogenesis — supports the body's own repair mechanisms rather than introducing external cells or substituting for them. No theatre, no arthroscopy, and no donor tissue are involved.

What the ultrasound-guided hip injection involves

Attending for a ChondroFiller hip injection is an outpatient appointment — no overnight stay, no theatre booking, and no general anaesthetic. The whole process takes place in clinic, typically under local anaesthetic, and patients are discharged the same day.

The appointment follows a clear sequence. The treating consultant reviews the pre-procedure MRI to confirm the defect location and plan the precise delivery point. The skin over the hip is prepared, local anaesthetic is administered, and the ChondroFiller solution is then placed using real-time ultrasound guidance — or fluoroscopic guidance where preferred — to position the collagen scaffold accurately at the cartilage surface. Intravenous antibiotic cover is given as standard protocol at the time of injection. After a short monitored period in clinic, patients are discharged with written aftercare instructions.

Because the injection is additive — the scaffold is laid over the worn cartilage surface rather than into a surgically prepared bed — no debridement of the joint is required beforehand, and no dry joint environment needs to be created. This is what makes the outpatient, image-guided approach workable for suitable candidates.

MSK Doctors consultants carry out ChondroFiller hip injections at both the Sleaford clinic (NG34), which houses the Regeneration Hub, and the Grantham centre (NG31). No GP referral is needed to book an assessment.

Recovery and the repair timeline

Patients often ask whether the injection will produce immediate relief — and the honest answer is that it is unlikely to. ChondroFiller works through biology, not mechanical cushioning, so the first weeks after the procedure are a period of active integration rather than rapid symptom change.

For four to six weeks post-injection, protected loading applies: reduced impact and avoided high-demand hip activity while the collagen scaffold begins to consolidate. Some patients find this phase inconvenient, particularly those with active lifestyles, and that concern is worth raising with the treating consultant before the appointment so expectations are set accurately.

The broader repair window — the three to six months during which stem cells recruited by the scaffold differentiate and deposit new fibrocartilage-like tissue — is where the functional gains develop. Improvement tends to be gradual rather than stepwise; many patients notice meaningful change from around three months onward, though the timeline varies with defect characteristics and individual biology.

Physiotherapy during this window helps optimise the loading signals that support cell recruitment and tissue maturation. A follow-up MRI or clinical review at an appropriate interval confirms whether repair is progressing as expected before activity levels are fully restored.

Outcomes for focal hip defects — what the evidence shows

The most directly relevant figure for the hip is a modified Harris Hip Score improvement of approximately +33 points in patients treated for focal cartilage damage including femoroacetabular impingement. A gain of that magnitude is clinically meaningful — Harris Hip Score improvements above 10 points are generally considered significant, and a 33-point shift moves patients from moderate functional limitation toward levels consistent with satisfying daily activity.

The hip study behind this figure has not been reported in full in the literature currently available: patient numbers, follow-up duration, and study design details remain undisclosed. The figure should be read as an indicative signal rather than the product of a large randomised trial.

Because the same scaffold and cellular mechanism operate across joints, structural evidence from larger knee cohorts provides useful — if not directly equivalent — context. Published series report MRI MOCART scores ranging from 70 to 87, indicating good defect filling and integration with surrounding native cartilage; critically, scores improve progressively, rising from a mean of 65.3 at four weeks to 81.6 at one year, confirming that scaffold maturation continues well beyond the early integration phase. In knee cohorts, IKDC functional scores improve by approximately 30 points over 12 months, with one prospective post-market study recording a mean gain of 32.4 points sustained — and marginally increased — at three-year follow-up.

More than 19,000 ChondroFiller procedures have now been performed globally across knee, hip, ankle, shoulder, and smaller joints. That scale supports confidence in the scaffold's real-world safety profile, though it does not imply that all cases were hip-specific or that outcomes translate uniformly across individual patients.

Functional gains depend on defect size, the quality of surrounding cartilage, and individual suitability — the variables that pre-procedure MRI review and consultant assessment are specifically designed to clarify before any treatment decision is made.

Getting assessed at MSK Doctors without a referral

For patients who match the profile covered throughout — an isolated focal defect, preserved cartilage margins, and realistic expectations about a months-long repair window — the evidence available suggests ChondroFiller injection can produce meaningful functional gains. An individual assessment is what establishes whether that profile applies in a specific case.

MSK Doctors is CQC-registered and rated 'Good' across all five key domains. Primary non-London assessment and treatment sites are Sleaford, Lincolnshire (NG34), which houses an Open MRI scanner and the Regeneration Hub, and Grantham (NG31). The assessment covers imaging review — or a new MRI where existing scans are outdated — followed by a consultant consultation to map defect extent and confirm suitability before any treatment decision is made. London-based patients may be seen through the London Cartilage Clinic.

You can book a consultant-led assessment directly at mskdoctors.com — no GP referral required.